NeoRx regains Nasdaq compliance

By Lisa Kerner

Erie, Pa., Feb. 23 - NeoRx Corp. said it has received notification from the Nasdaq Stock Market advising that the company has regained compliance with the Nasdaq Capital Market minimum bid price requirement.

According to a company news release, NeoRx maintained a closing bid price of $1.00 per share or greater for at least 10 consecutive trading days.

NeoRx was notified on Jan. 10 that it was not in compliance with Nasdaq rules because the closing bid price per share for the company's common stock had been below $1.00 for 30 consecutive trading days.

The company had 180 days, or until July 10, to regain compliance with the Nasdaq rule.

Seattle-based NeoRx is a specialty pharmaceutical company that develops and commercializes oncology drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.